Literature DB >> 8585712

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

D Sanglard1, K Kuchler, F Ischer, J L Pagani, M Monod, J Bille.   

Abstract

Azole antifungal agents, and especially fluconazole, have been used widely to treat oropharyngeal candidiasis in patients with AIDS. An increasing number of cases of clinical resistance against fluconazole, often correlating with in vitro resistance, have been reported. To investigate the mechanisms of resistance toward azole antifungal agents at the molecular level in clinical C. albicans isolates, we focused on resistance mechanisms related to the cellular target of azoles, i.e., cytochrome P450(14DM) (14DM) and those regulating the transport or accumulation of fluconazole. The analysis of sequential isogenic C. albicans isolates with increasing levels of resistance to fluconazole from five AIDS patients showed that overexpression of the gene encoding 14DM either by gene amplification or by gene deregulation was not the major cause of resistance among these clinical isolates. We found, however, that fluconazole-resistant C. albicans isolates failed to accumulate 3H-labelled fluconazole. This phenomenon was reversed in resistant cells by inhibiting the cellular energy supply with azide, suggesting that resistance could be mediated by energy-requiring efflux pumps such as those described as ATP-binding cassette (ABC) multidrug transporters. In fact, some but not all fluconazole-resistant clinical C. albicans isolates exhibited up to a 10-fold relative increase in mRNA levels for a recently cloned ABC transporter gene called CDR1. In an azole-resistant C. albicans isolate not overexpressing CDR1, the gene for another efflux pump named BENr was massively overexpressed. This gene was cloned from C. albicans for conferring benomyl resistance in Saccharomyces cerevisiae. Therefore, at least the overexpression or the deregulation of these two genes potentially mediates resistance to azoles in C. albicans clinical isolates from AIDS patients with oropharyngeal candidiasis. Involvement of ABC transporters in azole resistance was further evidenced with S. cerevisiae mutants lacking specific multidrug transporters which were rendered hypersusceptible to azole derivatives including fluconazole, itraconazole, and ketoconazole.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585712      PMCID: PMC162951          DOI: 10.1128/AAC.39.11.2378

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

Review 1.  Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics.

Authors:  R K Selander; D A Caugant; H Ochman; J M Musser; M N Gilmour; T S Whittam
Journal:  Appl Environ Microbiol       Date:  1986-05       Impact factor: 4.792

Review 2.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 3.  Molecular mechanisms of drug resistance in fungi.

Authors:  H Vanden Bossche; P Marichal; F C Odds
Journal:  Trends Microbiol       Date:  1994-10       Impact factor: 17.079

4.  Azole resistance in Candida albicans.

Authors:  J F Ryley; R G Wilson; K J Barrett-Bee
Journal:  Sabouraudia       Date:  1984

5.  "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1984-02       Impact factor: 3.365

6.  Expression of genes in yeast using the ADCI promoter.

Authors:  G Ammerer
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

7.  Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals.

Authors:  R Prasad; P De Wergifosse; A Goffeau; E Balzi
Journal:  Curr Genet       Date:  1995-03       Impact factor: 3.886

8.  DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS.

Authors:  F Barchiesi; R J Hollis; D A McGough; G Scalise; M G Rinaldi; M A Pfaller
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

9.  The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans.

Authors:  C A Hitchcock; K J Barrett-Bee; N J Russell
Journal:  J Gen Microbiol       Date:  1986-09

10.  Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans.

Authors:  B Hube; M Monod; D A Schofield; A J Brown; N A Gow
Journal:  Mol Microbiol       Date:  1994-10       Impact factor: 3.501

View more
  275 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

2.  Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol.

Authors:  G F Bammert; J M Fostel
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 3.  Fungal resistance.

Authors:  H Bernhardt; K Zimmermann; M Knoke
Journal:  Infection       Date:  1999       Impact factor: 3.553

Review 4.  Evolution of microbial pathogens.

Authors:  J Morschhäuser; G Köhler; W Ziebuhr; G Blum-Oehler; U Dobrindt; J Hacker
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

5.  Identification of azole-responsive genes by microarray technology: why are we missing the efflux transporter genes?

Authors:  D P Kontoyiannis; G S May
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 6.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Transcriptional analyses of antifungal drug resistance in Candida albicans.

Authors:  C N Lyons; T C White
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 8.  Strategies for the identification of virulence determinants in human pathogenic fungi.

Authors:  R Alonso-Monge; F Navarro-García; E Román; B Eisman; C Nombela; J Pla
Journal:  Curr Genet       Date:  2003-02-08       Impact factor: 3.886

9.  Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.

Authors:  P Phillips; S Shafran; G Garber; C Rotstein; F Smaill; I Fong; I Salit; M Miller; K Williams; J M Conly; J Singer; S Ioannou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

10.  Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect.

Authors:  Daisuke Kobayashi; Kei Kondo; Nobuyuki Uehara; Seiko Otokozawa; Naoki Tsuji; Atsuhito Yagihashi; Naoki Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.